-
Electronic (PDF)
-
Site License
-
Enterprisewide
Thyroid Cancer - Pipeline Review, H1 2012
Global Markets Direct, April 2012, Pages: 155
Thyroid Cancer – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Thyroid Cancer - Pipeline Review, H1 2012', provides an overview of the Thyroid Cancer therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer . 'Thyroid Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Thyroid Cancer .
- A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Thyroid Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Thyroid Cancer Therapeutic Products under Development, Key Players in Thyroid Cancer Therapeutics, Thyroid Cancer Pipeline Overview, Thyroid Cancer Pipeline, Thyroid Cancer Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thyroid Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Thyroid Cancer
Thyroid Cancer Therapeutics under Development by Companies
Thyroid Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Thyroid Cancer Therapeutics – Products under Development by Companies
Thyroid Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Thyroid Cancer Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Daiichi Sankyo Company, Ltd
Bio-Path Holdings, Inc.
Novartis AG
Eisai Co., Ltd.
Pfizer Inc.
Exelixis, Inc.
Bayer AG
OXiGENE, Inc.
Vascular Biogenics Ltd.
Globeimmune, Inc.
Thyroid Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E7080 - Drug Profile
Motesanib - Drug Profile
Nexavar - Drug Profile
Inlyta - Drug Profile
Caprelsa - Drug Profile
LBH589 - Drug Profile
Zelboraf - Drug Profile
Cabozantinib - Drug Profile
VB-111 - Drug Profile
BP-100-2.01 - Drug Profile
R935788 - Drug Profile
CP-4033 - Drug Profile
Gleevec + Dacarbazine + Xeloda - Drug Profile
ZD6474 - Drug Profile
Iressa - Drug Profile
GI-6207 - Drug Profile
BAY 43-9006 - Drug Profile
Gleevec - Drug Profile
Pazopanib Hydrochloride - Drug Profile
Romidepsin - Drug Profile
BAY43-9006 - Drug Profile
Gleevec - Drug Profile
Tanespimycin - Drug Profile
Lithium Carbonate - Drug Profile
XL184 + Rosiglitazone - Drug Profile
Temsirolimus + Sorafenib - Drug Profile
Depakote - Drug Profile
Irinotecan - Drug Profile
Thalidomide - Drug Profile
Afinitor - Drug Profile
Hydroxyurea + Fluorouracil + Paclitaxel + G-CSF + Radiation Therapy - Drug Profile
Recombinant thyrotropin - Drug Profile
Almita + Paclitaxel - Drug Profile
Zybrestat + Carboplatin + Paclitaxel - Drug Profile
LBH589 - Drug Profile
RAD001 - Drug Profile
Temsirolimus + Vinorelbine Ditartrate - Drug Profile
Valproic Acid - Drug Profile
Aplidin - Drug Profile
Aflibercept + Radiation theraphy - Drug Profile
Everolimus + Sorafenib - Drug Profile
Fostamatinib - Drug Profile
Sunitinib - Drug Profile
Prednisone + Thalidomide - Drug Profile
Sorafenib Tosylate - Drug Profile
SU011248 - Drug Profile
Sunitinib - Drug Profile
Lithium Carbonate - Drug Profile
AG-013736 - Drug Profile
Bortezomib - Drug Profile
Rosiglitazone Maleate - Drug Profile
Cisplatin + EPC2407 - Drug Profile
Sutent - Drug Profile
Cediranib + Lenalidomide - Drug Profile
CS-7017 + Paclitaxel - Drug Profile
Avastin + Doxorubicin - Drug Profile
Alimta + Paclitaxel - Drug Profile
ET-D5 - Drug Profile
Everolimus + SOM230 - Drug Profile
Pazopanib + Iodine I 131 - Drug Profile
Thalidomide - Drug Profile
Pazopanib + GSK1120212 - Drug Profile
Thyroid Cancer Therapeutics – Drug Profile Updates
Thyroid Cancer Therapeutics – Discontinued Products
Thyroid Cancer Therapeutics - Dormant Products
Thyroid Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Thyroid Cancer, H1 2012
Products under Development for Thyroid Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Amgen Inc., H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Bio-Path Holdings, Inc., H1 2012
Novartis AG, H1 2012
Eisai Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Exelixis, Inc., H1 2012
Bayer AG, H1 2012
OXiGENE, Inc., H1 2012
Vascular Biogenics Ltd., H1 2012
Globeimmune, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Thyroid Cancer Therapeutics – Drug Profile Updates
Thyroid Cancer Therapeutics – Discontinued Products
Thyroid Cancer Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Thyroid Cancer, H1 2012
Products under Development for Thyroid Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
